Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 38.39M shares rose 0.4% year over year, behind the +2.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
38.39M+0.0% QoQ
Last fiscal yearDec 2025
38.39M+4.3% YoY
LTMMar 2026
38.39M+2.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+4.3%——
3-year CAGR+14.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
38.39M USD
Year-over-year change
+4.3%
4-year CAGR
+17.1%

Weighted Avg Shares (Diluted) vs competitors

How OBIO compares with its peers on the latest reported figures

  • OBIO's LTM Mar 2026 weighted avg shares (diluted) of 38.39M shares is the 9th highest of the 11 companies compared; the peer median is 68.46M shares.
  • Its year-over-year change of +2.6% is the 9th highest of 11, against a peer median of +42.0%.
  • Over three fiscal years its annual growth of +14.7% compares with a peer median of +25.5%.
OBIO Competitors Peer median
Weighted Avg Shares (Diluted) for OBIO and competitors
Company Period LTM YoY 3-year CAGR
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202645.37M +27.3%+27.5%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +60.9%+599.3%
Peer median (excluding OBIO) 68.46M+42.0%+25.5%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.